Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA and Atezolizumab in Advanced NSCLC
NCT04919369Phase 1Completed
- Start
- Oct 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tretinoin and atezolizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Incidence of adverse events at 2 years. Started Oct 2021; status: completed.
02
Drugs
tretinoinatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04919369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919369.